Université de Montreal, Quebec, Canada.
McGill University Hospital Center, Montreal, Quebec, Canada.
Pain Physician. 2019 May;22(3):229-240.
Canada and the United States have the highest levels of prescription opioid consumption in the world. In an attempt to curb the opioid epidemic, a variety of interventions have been implemented. Thus far, evidence regarding their effectiveness has not been consolidated.
The objectives of this study were to: 1) identify interventions that target opioid prescribing; 2) assess and compare the effectiveness of interventions on opioid prescription and related harms; 3) determine the methodological quality of evaluation studies.
The study involved a systematic review of the literature including bibliographical databases and gray literature sources.
Systematic review including bibliographical databases and gray literature sources.
We searched MEDLINE, Embase, and LILACS databases from January 1, 2005 to September 23, 2016 for any intervention that targeted the prescription of opioids. We also examined websites of relevant organizations and scanned bibliographies of included articles and reviews for additional references. The target population was that of all health care providers (HCPs) or users of opioids with no restriction on indication. Endpoints were those related to process (implementation), outcomes (effectiveness), or impact. Sources were screened independently by 2 reviewers using pre-defined eligibility criteria. Synthesis of findings was qualitative; no pooling of results was conducted.
Literature search yielded 12,278 unique sources. Of these, 142 were retained. During full-text review, 75 were further excluded. Searches of the gray literature and bibliographies yielded 49 additional sources. Thus, a total of 95 distinct interventions were identified. Over half consisted of prescription monitoring programs (PMPs) and mainly targeted HCPs. Evaluation studies addressed mainly opioid prescription rate (30.6%), opioid use (19.4%), or doctor shopping or diversion (9.7%). Fewer studies considered overdose death (9.7%), abuse (9.7%), misuse (4.2%), or diversion (5.6%). Study designs consisted of cross-sectional surveys (23.3%), pre-post intervention (26.7%), or time series without a comparison group (13.3%), which limit the robustness of the evidence. Although PMPs and policies have been associated with a reduction in opioid prescription, their impact on appropriateness of use according to clinical guidelines and restriction of access to patients in need is inconsistent. Continuing medical education (CME) and pain management programs were found effective in improving chronic pain management, but studies were conducted in specific settings. The impact of interventions on abuse and overdose-death is conflicting.
Due to the very large number of publications and programs found, it was difficult to compare interventions owing to the heterogeneity of the programs and to the methodologies of evaluation studies. No assessment of publication bias was done in the review.
Evidence of effectiveness of interventions targeting the prescription of opioids is scarce in the literature. Although PMPs have been associated with a reduction in the overall prescription rates of Schedule II opioids, their impact on the appropriateness of use taking into consideration benefits, misuse, legal and illegal use remains elusive. Our review suggests that existing interventions have not addressed all determinants of inappropriate opioid prescribing and usage. A well-described theoretical framework would be the backdrop against which targeted interventions or policies may be developed.
Opioid, prescription, abuse, misuse, diversion, interventions, prescription monitoring programs.
加拿大和美国是世界上处方类阿片类药物消费最高的国家。为了控制阿片类药物泛滥,已经实施了各种干预措施。到目前为止,关于它们的有效性的证据尚未得到综合。
本研究的目的是:1)确定针对阿片类药物处方的干预措施;2)评估和比较干预措施对阿片类药物处方和相关危害的影响;3)确定评估研究的方法学质量。
本研究对文献进行了系统评价,包括文献数据库和灰色文献来源。
系统评价包括文献数据库和灰色文献来源。
我们检索了 MEDLINE、Embase 和 LILACS 数据库,从 2005 年 1 月 1 日至 2016 年 9 月 23 日,以获取任何针对阿片类药物处方的干预措施。我们还检查了相关组织的网站,并扫描了纳入文章和综述的参考文献,以获取其他参考文献。目标人群是所有医疗保健提供者(HCPs)或阿片类药物使用者,没有对适应症的限制。终点是与过程(实施)、结果(有效性)或影响相关的那些。来源由两名独立的审查员使用预先定义的合格标准进行筛选。研究结果的综合是定性的;没有进行结果的汇总。
文献检索产生了 12278 个独特的来源。其中,142 个被保留。在全文审查过程中,又排除了 75 个。对灰色文献和参考文献的搜索产生了另外 49 个来源。因此,总共确定了 95 种不同的干预措施。其中一半以上是处方监测计划(PMPs),主要针对医疗保健提供者。评估研究主要针对阿片类药物处方率(30.6%)、阿片类药物使用(19.4%)或医生购物或转移(9.7%)。较少的研究考虑了过量死亡(9.7%)、滥用(9.7%)、误用(4.2%)或转移(5.6%)。研究设计包括横断面调查(23.3%)、干预前后(26.7%)或无对照组的时间序列(13.3%),这限制了证据的稳健性。尽管 PMP 和政策与减少阿片类药物处方有关,但它们对根据临床指南适当使用以及限制有需要的患者获得的影响并不一致。继续医学教育(CME)和疼痛管理计划被发现能有效改善慢性疼痛管理,但这些研究是在特定环境中进行的。干预措施对滥用和过量死亡的影响存在冲突。
由于发表的文章和方案数量非常多,由于方案的异质性和评估研究的方法学,很难对干预措施进行比较。在综述中没有对发表偏倚进行评估。
关于针对阿片类药物处方的干预措施的有效性的证据在文献中很少。尽管 PMP 与 II 类阿片类药物的总体处方率降低有关,但它们对考虑到益处、误用、合法和非法使用的适当使用的影响仍不清楚。我们的综述表明,现有的干预措施并没有解决所有不适当的阿片类药物处方和使用的决定因素。一个描述良好的理论框架将是针对特定干预措施或政策制定的背景。
阿片类药物,处方,滥用,误用,转移,干预,处方监测计划。